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Little is known about the effects of a pandemic on non-elective neurosurgical practices, which have
continued under modified conditions to reduce the spread of COVID-19. This knowledge might be
critical for the ongoing second coronavirus wave and potential restrictions on health care. We aimed to
determine the incidence and 30-day mortality rate of various non-elective neurosurgical procedures during
the COVID-19 pandemic. A retrospective, multi-centre observational cohort study among neurosurgical
centres within Austria, the Czech Republic, and Switzerland was performed. Incidence of neurosurgical
emergencies and related 30-day mortality rates were determined for a period reflecting the peak pandemic
of the first wave in all participating countries (i.e. March 16th-April 15th, 2020), and compared to the
same period in prior years (2017, 2018, and 2019). A total of 4,752 emergency neurosurgical cases were
reviewed over a 4-year period. In 2020, during the COVID-19 pandemic, there was a general decline in the
incidence of non-elective neurosurgical cases, which was driven by a reduced number of traumatic brain
injuries, spine conditions, and chronic subdural hematomas. Thirty-day mortality did not significantly
increase overall or for any of the conditions examined during the peak of the pandemic. The neurosurgical
community in these three European countries observed a decrease in the incidence of some neurosurgical
emergencies with 30-day mortality rates comparable to previous years (2017-2019). Lower incidence of
neurosurgical cases is likely related to restrictions placed on mobility within countries, but may also
involve delayed patient presentation.
DOI: https://doi.org/10.1038/s41598-021-85526-6






The following work is licensed under a Creative Commons: Attribution 4.0 International (CC BY 4.0)
License.
Originally published at:
Grassner, Lukas; Petr, Ondra; Warner, Freda M; Dedeciusova, Michaela; Mathis, Andrea Maria; Ping-
gera, Daniel; et al; Serra, C (2021). Trends and outcomes for non-elective neurosurgical procedures in





Scientific Reports |         (2021) 11:6171  | https://doi.org/10.1038/s41598-021-85526-6
www.nature.com/scientificreports
Trends and outcomes 
for non‑elective neurosurgical 
procedures in Central Europe 
during the COVID‑19 pandemic
Lukas Grassner1,34*, Ondra Petr1,34, Freda M. Warner2,34, Michaela Dedeciusova3,34, 
Andrea Maria Mathis4,34, Daniel Pinggera1, Sina Gsellmann5, Laura C. Meiners5, 
Sascha Freigang6, Michael Mokry6, Alexandra Resch7, Thomas Kretschmer7, 
Tobias Rossmann8, Francisco Ruiz Navarro8, Andreas Gruber8, Mathias Spendel9, 
Peter A. Winkler9, Franz Marhold10, Camillo Sherif10, Jonathan P. Wais11, Karl Rössler11, 
Wolfgang Pfisterer12, Manfred Mühlbauer12, Felipe A. Trivik‑Barrientos13, Sebastian Rath13, 
Richard Voldrich3, Lukas Krska14, Radim Lipina14, Martin Kerekanic15, Jiri Fiedler15, 
Petr Kasik16, Vladimir Priban16, Michal Tichy17, Petr Krupa18, Tomas Cesak18, Robert Kroupa19, 
Andrej Callo20, Pavel Haninec20, Daniel Pohlodek21, David Krahulik21, Alena Sejkorova22, 
Martin Sames22, Josef Dvorak23, Petr Suchomel23, Robert Tomas24, Jan Klener24, 
Vilem Juran25, Martin Smrcka25, Petr Linzer26, Miroslav Kaiser27, Dusan Hrabovsky28, 
Radim Jancalek28, Vincens Kälin29, Oliver Bozinov29, Cedric Niggli30, Carlo Serra30, 
Ramona Guatta31, Dominique E. Kuhlen31, Stefan Wanderer32, Serge Marbacher32, 
Alexandre Lavé33, Karl Schaller33, Clarinde Esculier4, Andreas Raabe4,35, John L. K. Kramer2,35, 
Claudius Thomé1,35 & David Netuka3,35 
OPEN
1Department of Neurosurgery, Medical University Innsbruck, Anichstrasse 35, MZA 3rd floor, 6020 Innsbruck, 
Austria. 2International Collaboration On Repair Discoveries (ICORD), University of British Columbia, Vancouver, 
BC, Canada. 3Department of Neurosurgery and Neuro-Oncology, 1St Medical Faculty, Charles University, Central 
Military Hospital, Prague, Czech Republic. 4Department of Neurosurgery, Inselspital Bern, Bern University Hospital, 
Bern, Switzerland. 5Department of Neurosurgery, Landeskrankenhaus Feldkirch, Feldkirch, Austria. 6Department 
of Neurosurgery, Medical University Graz, Graz, Austria. 7Department of Neurosurgery & Neurorestauration 
Klinikum Klagenfurt, Klagenfurt, Austria. 8Department of Neurosurgery, Kepler University Hospital GmbH, 
Johannes Kepler University, Linz, Austria. 9Department of Neurosurgery, Christian Doppler Clinic, Paracelsus 
Medical University, Salzburg, Austria. 10Department of Neurosurgery, University Hospital of St, Karl Landsteiner 
University of Health Sciences, St. Poelten, Austria. 11Department of Neurosurgery, Medical University of Vienna, 
Vienna, Austria. 12Department of Neurosurgery, Klinik Donaustadt, Vienna, Austria. 13Department of Neurosurgery, 
General Hospital Wiener Neustadt, Wiener Neustadt, Austria. 14Department of Neurosurgery, University Hospital 
Ostrava, Ostrava, Czech Republic. 15Department of Neurosurgery, Ceske Budejovice Hospital, Ceske Budejovice, 
Czech Republic. 16Department of Neurosurgery, Pilsen University Hospital, Pilsen, Czech Republic. 17Department of 
Neurosurgery, Motol University Hospital, Motol, Czech Republic. 18Department of Neurosurgery, University Hospital 
Hradec Kralove, Hradec Kralove, Czech Republic. 19Unit of Neurosurgery, Municipal Hospital - Ostrava Fifejdy, Ostrava 
Fifejdy, Czech Republic. 20Department of Neurosurgery, University Hospital Kralovske Vinohrady, Prague, Czech 
Republic. 21Department of Neurosurgery, University Hospital Olomouc, Olomouc, Czech Republic. 22Department of 
Neurosurgery, Usti Nad Labem Hospital, Prague, Czech Republic. 23Department of Neurosurgery, Liberec Hospital, 
Prague, Czech Republic. 24Unit of Neurosurgery, Homolka Hospital, Prague, Czech Republic. 25Department of 
Neurosurgery, University Hospital Brno and Masaryk University, Prague, Czech Republic. 26Unit of Neurosurgery, Zlin 
Hospital, Prague, Czech Republic. 27Unit of Neurosurgery, Pardubice Hospital, Prague, Czech Republic. 28Department 
of Neurosurgery, St. Anne’s University Hospital Brno and Masaryk University, Prague, Czech Republic. 29Department of 
Neurosurgery, Kantonspital St. Gallen, St. Gallen, Switzerland. 30Department of Neurosurgery, Clinical Neuroscience 
Center, University Hospital Zurich, Zurich, Switzerland. 31Clinic of Neurosurgery, Neurocenter of Southern Switzerland, 
Lugano, Switzerland. 32Department of Neurosurgery, Kantonspital Aarau, Aarau, Switzerland. 33Department of 
Neurosurgery, Geneva University Hospitals, Geneva, Switzerland. 34These authors contributed equally: Lukas Grassner, 
Ondra Petr, Freda M. Warner, Michaela Dedeciusova and Andrea Maria Mathis. 35These authors jointly supervised this 
work: Andreas Raabe, John L. K. Kramer, Claudius Thomé and David Netuka. *email: Lukas.grassner@googlemail.com
2
Vol:.(1234567890)
Scientific Reports |         (2021) 11:6171  | https://doi.org/10.1038/s41598-021-85526-6
www.nature.com/scientificreports/
The world currently faces the novel severe acute respiratory syndrome coronavirus 2 pandemic. 
Little is known about the effects of a pandemic on non‑elective neurosurgical practices, which have 
continued under modified conditions to reduce the spread of COVID‑19. This knowledge might be 
critical for the ongoing second coronavirus wave and potential restrictions on health care. We aimed 
to determine the incidence and 30‑day mortality rate of various non‑elective neurosurgical procedures 
during the COVID‑19 pandemic. A retrospective, multi‑centre observational cohort study among 
neurosurgical centres within Austria, the Czech Republic, and Switzerland was performed. Incidence of 
neurosurgical emergencies and related 30‑day mortality rates were determined for a period reflecting 
the peak pandemic of the first wave in all participating countries (i.e. March 16th–April 15th, 2020), 
and compared to the same period in prior years (2017, 2018, and 2019). A total of 4,752 emergency 
neurosurgical cases were reviewed over a 4‑year period. In 2020, during the COVID‑19 pandemic, 
there was a general decline in the incidence of non‑elective neurosurgical cases, which was driven by 
a reduced number of traumatic brain injuries, spine conditions, and chronic subdural hematomas. 
Thirty‑day mortality did not significantly increase overall or for any of the conditions examined during 
the peak of the pandemic. The neurosurgical community in these three European countries observed a 
decrease in the incidence of some neurosurgical emergencies with 30‑day mortality rates comparable 
to previous years (2017–2019). Lower incidence of neurosurgical cases is likely related to restrictions 
placed on mobility within countries, but may also involve delayed patient presentation.
The world currently faces a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, known 
as COVID-19. Following the initial outbreak, health care workflow was altered globally in many  aspects1,2. Many 
countries placed elective surgical interventions on hold as a precaution to reduce its  spread3–5. Non-elective, 
emergency surgeries, however, were continued as needed with revised management practices to protect patients, 
their families, and health care  providers6. Introduced modifications included changes to work sequences in out- 
and inpatient services, pre- and perioperative changes, and faculty contingency  planning7. As acute neurosurgical 
care involves both live-saving procedures and semi-urgent interventions to avoid lasting neurologic deficits, the 
triage of non-elective neurosurgical indications can pose a particular challenge under unprecedented circum-
stances, and potentially limited intensive care  resources8.
In response to COVID-19, an abundance of viewpoints, guidelines, and reviews on best surgical practices 
during a pandemic have been  published3,9–16. Comparatively fewer original research studies have documented 
the impact of the current pandemic on the incidence and surgical outcomes of non-elective cases. They have, to 
this point, focused on complications arising in patients with COVID-19 following  surgery17–23. Notably lacking 
are studies exploring whether the systemic response to COVID-19 altered incidence and outcomes for uninfected 
patients undergoing non-elective/emergent surgical procedures. This information is critical to evaluate protocols 
for the ongoing second wave of COVID-1924,25.
The aim of the current study was to examine incidence and outcomes for non-elective emergent neurosurgi-
cal cases in COVID-19-negative patients during the first wave of the pandemic. A retrospective analysis was 
performed of most neurosurgical procedures across three European countries (Austria, the Czech Republic, and 
Switzerland) during the initial height of the COVID-19 pandemic (March 16 to April 15, 2020). The primary 
analysis addressed incidence and 30-day mortality in non-elective neurosurgical cases compared to three previ-
ous years.
Methods
Our analysis included data from all neurosurgical centres in the Czech Republic, and the majority in Austria (10 
of 11) and Switzerland (6 of 7), thus covering a population of almost 30 million people. During the outbreak these 
countries postponed elective surgeries, and intensive care resources were redistributed or reserved. Attempts were 
made to continue non-elective surgeries; however, in the absence of guidelines, it was unclear which procedures 
needed to be performed and what time frames were acceptable to initiate intervention. Despite the prevalence 
of COVID-19 cases in these countries, there were no obvious shortages in intensive care capacities during this 
time. Notably, the work flow was influenced heavily in the early phase of the pandemic with all related uncertain-
ties. Information on all non-elective, emergent cranial and spinal neurosurgical procedures performed during 
March 16th–April 15th, 2020 was collected. This period was selected to reflect the culmination of the pandemic in 
these areas. Noteworthy, similar restrictions were applied in all assessed countries over the selected time period. 
Cases from identical time periods in 2017–2019 were analysed for reference. Ethical approval was obtained by 
the coordinating centres from each country (Ethikkommission Nummer der Medizischen Universität Innsbruck 
1110/2020 in Austria, Etická komise FN Ostrava 448/2020 in the Czech Republic, and Kantonale Ethikkommis-
sion für die Forschung Bern 2020–01,433 in Switzerland). All research was performed in accordance with the 
local regulations as well as in Accordance with the declaration of Helsinki. Informed consent was waived by the 
approving committees.
Patients. Demographic and surgical data were retrospectively collected in all participating centres. Demo-
graphic data elements included age, sex, and 30-day mortality. Conservatively managed patients were not 
included in our study. Inclusion/exclusion criteria are shown in Table 1. Cases were defined as: 1) traumatic 
brain injury (TBI) requiring any emergent neurosurgical intervention (i.e. monitoring for intracranial pressure, 
decompressive craniectomy, etc.), 2) chronic subdural hematomas (cSDH) in need of surgical evacuation due 
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to the mass effect and/or neurological symptoms, 3) aneurysmal or non-aneurysmal subarachnoid haemor-
rhage, and other neurovascular pathologies, including arteriovenous malformations, arteriovenous fistula, and 
cavernous malformation requiring rapid treatment (i.e. latest within 2 weeks after onset of symptoms), 4) spinal 
procedures requiring non-elective surgical management involving degenerative spine disease with new onset 
or acute worsening of neurological symptoms (motor deficits and/or cauda equina syndrome, signs of spinal 
cord compression), infectious spine disease, spine tumours including metastasis, extradural, intradural and 
intramedullary tumours, as well as traumatic spine injuries with or without neurological symptoms, 5) new 
onset hydrocephalus or acute worsening in pre-existing hydrocephalus (e.g. shunt dysfunction), and 6) newly 
diagnosed intracranial lesions including low- or high-grade gliomas, meningioma, infarction in need for decom-
pressive craniectomy, intracranial hematomas or abscesses requiring rapid or non-elective surgical scheduling 
(i.e. latest within 3 weeks after diagnosis or symptom onset).
Statistics. The number of total incident cases, and number within each condition, were determined in each 
year, separately for each country. Chi-square tests were used to test for differences in incidence across the years, 
and significant differences (p < 0.05) were further examined using standardized residuals. Rates of 30-day mor-
tality were determined for each year, and within each condition separately for both countries. Thirty-day mortal-
ity was analysed using logistic regression with year (2020 vs. 2017–2019) as an independent variable. All models 
were adjusted for age (0–18, 18–39, 40–64, 65–74, and 75 + years old) and sex.
Results
The participating centres in Austria, the Czech Republic, and Switzerland recorded 1,631, 2,234, and 887 non-
elective neurosurgical cases, respectively. Female patients represented 44% of the sample in Austria and Swit-
zerland, and 41% in the Czech Republic. The median age in Austria and the Czech Republic was 61 years (range: 
0–95 in Austria, 0–96 in the Czech Republic), and 65 for Switzerland (17–96). One Austrian centre could only 
provide information on spine cases for 2019 and 2020, and thus was removed from descriptions and analyses of 
total cases and spine cases, but was included for the other conditions.
Incidence. The overall incidence of neurosurgical cases trended downwards in Austria and the Czech Repub-
lic in 2020. Chi-squared analyses revealed that significant differences in incidence rates occurred for cSDH, 
spine, acute hydrocephalus, and tumour cases in Austria, and in TBI and cSDH in the Czech Republic. These 
differences were driven by lower incidences in 2020 for all conditions in Austria, excluding tumours and other 
intracranial lesions. In the Czech Republic, TBI increased in 2019, then reached a 4 year low in 2020. There were 
no significant trends for incident cases in Switzerland (Table 2).
30‑day mortality. Of the recorded cases in Austria and the Czech Republic, 1,616 (99% of total) in Austria, 
2,222 (99%) in the Czech Republic, and 875 (97%) in Switzerland, were included in the logical regression analy-
sis of 30-day mortality. Logistic regression models revealed that the year 2020 was not significantly associated 
with any increased odds of 30-day mortality. In fact, TBI within the Czech Republic had a significant lowered 
30-day mortality (Tables 3 and 4).
Discussion
Our observations indicate a general trend toward reduced numbers of non-elective, emergency neurosurgical 
cases during the COVID-19 pandemic in Austria, Switzerland and the Czech Republic. This was primarily driven 
by a decreased incidence of conditions commonly associated with traumatic aetiologies, including brain injuries, 
spine conditions, and chronic subdural hematomas. Although variable across the study period (2017–2020), 
30-day mortality during COVID-19 in Austria, the Czech Republic, and Switzerland did not significantly increase 
overall or for any condition compared to recent prior years. Despite the challenges of delivering health services 
and intensive care during the COVID-19  pandemic8,26, our data indicate that emergency neurosurgical care 
could still be provided in these three countries.
The decreased incidence of selected neurosurgical conditions does not come as a surprise during a time when 
Austria the Czech Republic and Switzerland imposed relatively similar societal “lock down” measures to reduce 
the spread of COVID-19. Nevertheless, based on data representative of three European countries, this study 
is the first to quantify the extent to which COVID-19 impacted emergent surgical practice. The most obvious 
Table 1.  Inclusion and exclusion criteria.
Inclusion Exclusion
Any traumatic brain injury requiring surgical intervention
Chronic subdural hematoma requiring surgical evacuation
(Aneurysmal and non-aneurysmal) Subarachnoid haemorrhage and other neu-
rovascular pathologies (arteriovenous malformation, dural arteriovenous fistula, 
cavernoma) requiring endovascular and/or neurosurgical intervention
Any (degenerative, traumatic, infectious, tumour) spine pathology requiring 
non-elective neurosurgical intervention
New-onset or acute worsening in patients with hydrocephalus
Intracranial lesions (including low- and high-grade gliomas, meningiomas, 




Any procedure not meeting predefined inclusion criteria
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explanation is restricted mobility and outdoor activity within countries. This, in turn, led to fewer traumatic 
accidents (e.g., motor vehicle) and a subsequent reduction in brain and spinal cord  injuries27–29.
On the other hand, the lower incidence of acute hydrocephalus and spine cases in Austria plus the reduced 
number of interventions for cSDH warrants further attention. Chronic SDH is thought to result from minor 
trauma weeks or months earlier in the elderly and may thus not reflect traumatic injuries in the lock-down period 
but rather delayed presentation of patients to health care  providers28. This may be particularly applicable for an 
insidious disease like cSDH. Thus, there is the possibility that individuals with signs of symptoms of these condi-
tions were hesitant to seek medical care during COVID-19. This was reported as a potential factor in Northern 
Italy in patients with acute coronary  syndrome30. Faced with concerns and uncertainty regarding transmission of 
COVID-19, staying home may reasonably have been perceived as a safer alternative to treatment for symptoms 
such as headaches, dizziness, and confusion related to trauma. While this is a difficult hypothesis to explicitly test 
with our data, the incidence of non-traumatic cases did not significantly decrease in 2020 compared to reference 
years in either Austria, the Czech Republic or Switzerland (2017–2019). This is particularly notable for the inci-
dence of tumours, which paradoxically increased in Austria in 2020. Had a reduction in the incidence of tumours 
been observed, one might reasonably speculate that reluctance to seek medical care served as a contributing fac-
tor; in the absence of such an effect, reduced incidence is most likely attributable to mobility restrictions imposed 
at the societal level that led to fewer traumatic injuries requiring neurosurgical  intervention27. Importantly, all 
analysed countries were not as severely hit by the pandemic as others, and intensive care capacities were available 
across all regions. Further, most non-elective cases need intensive care measures postoperatively. Neurological 
manifestations of the COVID-19 pandemic need to be kept in mind as  well31,32.
From a health care delivery standpoint, it was very encouraging to find that the odds of 30-day mortality did 
not increase in 2020 in these countries, for any condition. Due to altered management practices, issues related 
to the quality of care for patients with neurooncological diseases during the pandemic have been  raised33. Our 
Table 2.  The incidence of non-elective neurosurgical cases in Austria, Czech Republic and Switzerland from 
March 16th until April 15th 2017–2020. TBI Traumatic brain injury, cSDH chronic subdural hematoma, SAH 
subarachnoid haemorrhage and other vascular pathologies. *P-values derived from chi-square tests.
2017 2018 2019 2020 P-value*
Austria
Total cases 400 417 392 345 0.06
Condition
TBI 42 43 26 27 0.06
cSDH 72 63 62 38 0.01
SAH 26 47 37 41 0.10
Spine 104 110 111 71 0.01
Acute hydrocephalus 59 42 58 28 0.003
Tumour and other intracranial lesions 105 126 105 152 0.007
Czech Republic
Total cases 586 551 584 513 0.10
Condition
TBI 74 68 98 48  < 0.001
cSDH 87 110 84 53 0.002
SAH 59 59 66 63 0.90
Spine 175 139 135 153 0.09
Acute hydrocephalus 53 42 59 45 0.31
Tumour and other intracranial lesions 138 133 142 151 0.74
Switzerland
Total cases 243 220 208 216 0.38
Condition
TBI 22 24 16 18 0.57
cSDH 38 37 36 41 0.95
SAH 30 14 21 18 0.08
Spine 61 64 47 49 0.27
Acute hydrocephalus 24 27 24 26 0.97
Tumour and other intracranial lesions 68 54 64 64 0.63
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results, however, suggest that methods imposed to deliver care during COVID-19 in Austria, the Czech Republic, 
and Switzerland did not have major negative consequences.
Major strengths of this study were the large sample size, inclusion of multiple reference periods (2017–2019) 
for comparison to COVID-19, and representation of nearly all neurosurgical centres in Austria, the Czech 
Republic, and Switzerland. The interpretation of our data is limited, however, by the observational and ret-
rospective nature of the study. Further, only patients that received surgical care were analysed. Future studies 
should consider the extent to which societal measures associated with COVID-19 may have influenced access 
to health care services by exploring other outcomes, including disease severity. Additionally, lengthening the 
duration of data acquisition beyond the 1-month window would allow the detection of a “rebound” in cases that 
were reduced by the pandemic. Hence, surgical prioritization after the pandemic is important  too34. Further, 
one should keep in mind that COVID-19 per se causes significant neurological  manifestations35,36 and some 
patients might need surgical care.
Conclusion
The world continues to face major challenges in managing COVID-19, which also include potential restrictions 
of health care services. Hence, it is uplifting to know that the neurosurgical community’s response to the initial 
phase of the pandemic, in at least three European countries, maintained high standards of care and low rates 
of acute mortality. Nevertheless, the potential of delayed patient presentation warrants further investigation as 
emergent neurosurgical care needs to be provided at all times.
Table 3.  The 30-day mortality rates from non-elective neurosurgical cases in Austria, Czech Republic 
and Switzerland from 2017–2020. TBI Traumatic brain injury, cSDH chronic subdural hematoma, SAH 
subarachnoid haemorrhage and other vascular pathologies.
2017 2018 2019 2020
Austria
All conditions 6.0% 6.0% 3.6% 6.5%
Condition
TBI 12.2% 14.3% 3.8% 7.7%
cSDH 2.9% 1.6% 0.0% 5.3%
SAH 8.0% 13.3% 16.2% 9.8%
Spine 0.0% 0.9% 0.0% 1.4%
Acute hydrocephalus 8.5% 0.0% 3.4% 7.4%
Tumour and other intracranial lesions 9.7% 8.7% 6.7% 8.7%
Czech Republic
All conditions 5.1% 7.1% 8.4% 4.5%
Condition
TBI 13.5% 20.9% 17.3% 4.3%
cSDH 2.3% 4.5% 6.0% 5.9%
SAH 15.3% 5.1% 6.1% 10.0%
Spine 1.1% 2.9% 3.7% 1.3%
Acute hydrocephalus 5.7% 9.5% 8.5% 6.7%
Tumour and other intracranial lesions 2.9% 6.8% 9.3% 4.6%
Switzerland
All conditions 7.7% 6.9% 9.8% 8.9%
Condition
TBI 18.2% 13.0% 18.8% 16.7%
cSDH 0.0% 0.0% 2.9% 2.4%
SAH 24.1% 21.4% 23.8% 16.7%
Spine 1.8% 1.6% 4.3% 6.3%
Acute hydrocephalus 4.2% 11.1% 16.7% 16.0%
Tumour and other intracranial lesions 7.5% 9.3% 7.8% 7.8%
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